ADC Therapeutics SA filed a Form S-3 registration statement with the SEC on November 9, 2026, to register 61,000,000 common shares for resale by selling shareholders who acquired the securities through securities purchase agreements dated October 7, 2026.
Key Highlights
- 61,000,000 shares registered: The prospectus covers an aggregate of 61,000,000 common shares offered by selling shareholders, not by the company itself.
- Two share components: The registered shares consist of 12,911,347 common shares and 48,088,653 common shares issuable upon exercise of pre-funded warrants, both issued under the October 7, 2026 securities purchase agreements.
- No company proceeds from resales: According to the filing, ADC Therapeutics will not receive any proceeds from the sale of common shares by the selling shareholders.
- Potential warrant exercise proceeds: If the pre-funded warrants are exercised in cash, the company disclosed it may receive up to an aggregate of CHF 3,847,092, to be used for working capital and general corporate purposes.
- Smaller reporting company: The registrant identified itself as a non-accelerated filer and a smaller reporting company, and not an emerging growth company.
- NYSE-listed: The company's common shares are listed on NYSE:ADCT.
ADC Therapeutics Seeks to Register October 2026 Private Placement Shares for Resale
ADC Therapeutics SA, a Switzerland-incorporated biopharmaceutical company, filed a Form S-3 registration statement on November 9, 2026, covering the resale of 61,000,000 common shares by selling shareholders. According to the filing, the registration is being made as required by securities purchase agreements dated October 7, 2026, entered into with the selling shareholders. The shares being registered were already issued and sold to those shareholders under those agreements.
The filing states that the 61,000,000 shares consist of two components: 12,911,347 common shares that have already been issued, and 48,088,653 common shares issuable upon the exercise of pre-funded warrants. The selling shareholders may offer their shares "from time to time" at prevailing market prices, at prices different than prevailing market prices, or at privately negotiated prices, as described in the prospectus's "Plan of Distribution" section. The filing notes that the company "does not know whether, when or the extent to which the selling shareholders will sell the common shares."
ADC Therapeutics disclosed that it will not receive proceeds from the resale of shares by selling shareholders. However, the filing indicates the company "may receive up to an aggregate of CHF 3,847,092" if the pre-funded warrants are exercised for cash, with those proceeds intended for working capital and general corporate purposes. The prospectus also notes that selling shareholders will bear any brokerage commissions or similar charges from their sales. The company's principal executive offices are located at Route de la Corniche 3B, 1066 Epalinges, Switzerland, with an agent for service of process at 430 Mountain Avenue, New Providence, New Jersey.
What Was Disclosed
ADC Therapeutics filed an S-3 registration statement to permit resale of 61,000,000 common shares, comprising 12,911,347 already-issued shares and 48,088,653 shares underlying pre-funded warrants, issued through private securities purchase agreements signed October 7, 2026.



Please wait processing your request...